BCL2 and breast carcinoma: In addition, we further examined the expression of MDA-MB-231 breast cancer cell proliferation, stemness markers and cell cycle–related proteins after the addition of MK-2206 and found that MK-2206 significantly decreased the expression of the Bcl-2, OCT4, NANOG, SOX2, CDK1, cyclin A2, and cyclin B1 proteins, while GluOC reversed the effect of MK-2206 (Fig. 7i and p).